Back

Impact of mavacamten on left atrial remodeling in obstructive hypertrophic cardiomyopathy: data from 3 portuguese centers

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibition in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ines Miranda

Hospital Professor Doutor Fernando Fonseca, Amadora (Portugal)

5 More presentations in this session

Presentation thumbnail
One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy
Doctor G. Bonacchi (Florence, IT)
Abstract Slides
Presentation thumbnail
Atrial fibrillation during mavacamten treatment in obstructive hypertrophic cardiomyopathy in the real-world: data from the multicenter MARVEL.HU registry on 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract Slides
Presentation thumbnail
Real world safety and efficacy of mavacamten for hypertrophic obstructive cardiomyopathy: the SWISS-MAVA cohort
Doctor D. Jensen (Zurich, CH)
Abstract Slides
Presentation thumbnail
Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Real-world experience with mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy
Doctor S. Hoss (Petah Tikva, IL)
Abstract Slides

Access the full session

Session thumbnail
Cardiac myosin inhibition in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of mavacamten on left atrial function in hypertrophic obstructive cardiomyopathy
13 December 2024
thumbnail
Congress Presentation
Left ventricular remodeling in aortic stenosis patients referred for surgical aortic valve replacement
28 August 2022
thumbnail
Congress Presentation
Impact on atrial remodeling of dapagliflozin in patients with heart failure (MODA TRIAL): baseline clinical characteristics
20 May 2023
thumbnail
Congress Presentation
Reverse structural and functional left atrial remodeling after successful catheter ablation for paroxysmal atrial fibrillation.
13 December 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources